Flecainide

In patients without structural heart disease, the label covers prevention of disabling PSVT (including AV nodal reentry and accessory-pathway reentry) and disabling paroxysmal AF / flutter. It also covers documented ventricular arrhythmias judged life-threatening, such as sustained VT, after individual benefit / risk assessment; initiation for sustained VT requires hospitalization with rhythm monitoring. Improved survival or prevention of sudden death has not been established.

Do not use for recent MI or less severe ventricular arrhythmias; chronic AF is not recommended in the selected label. For AF maintenance, official 2023 guidance considers flecainide reasonable without previous MI, known / suspected significant structural disease or ventricular scar / fibrosis; it recommends against use with prior MI or significant structural disease, including HFrEF with LVEF≤40%. These broader guidance restrictions are not narrowed to the older label’s “recent MI” wording.

This profile covers selected U.S. immediate-release tablets and maintenance regimens. Guideline “pill-in-the-pocket” cardioversion requires prior monitored testing and a concomitant AV nodal blocker in appropriate patients; it is not the routine maintenance regimen. Numeric conversion / loading recipes, foreign IV / extended-release products and compounded preparation recipes are excluded.

For severe renal impairment (label CrCl≤35 mL /min /1.73 m²), start 100 mg once daily or 50 mg twice daily and obtain frequent levels. The label’s separate less-severe renal paragraph says 100 mg every 12 hours; this is not a universal replacement for the 50 mg twice-daily PSVT / PAF start, and indication plus organ status must be reconciled by the prescriber. Renal titration waits for plateau, potentially>4 days. Significant hepatic impairment generally precludes use unless benefit clearly outweighs risk; if used, require early / frequent levels and cautious plateau-based changes. With amiodarone reduce the usual flecainide dose 50%, closely monitor and strongly consider level-guided adjustment.

Pediatric randomized-trial safety / effectiveness is unestablished, but the label describes specialist-supervised dosing: under 6 months approximately 50 mg /m² /day in two or three equal doses; over 6 months initial 100 mg /m² /day, maximum 200 mg /m² /day. The label does not explicitly assign the exact 6 month boundary, so it is not resolved here by inventing an age rule. Initiation requires hospital rhythm monitoring and an experienced pediatric cardiologist; dose changes and growth require ECG / trough checks. Milk changes can markedly alter infant exposure.

Normal-organ steady state may take 3–5 days; organ impairment can take longer. Adult troughs in successfully treated patients were usually 0.2–1 microgram /mL, with increased adverse risk above 1; these observations are not a universal therapeutic algorithm. Severe renal / hepatic disease requires level monitoring; amiodarone strongly warrants it. Do not change doses or switch antiarrhythmics using a self-directed half-life calculation.

Formal selected label contraindications are second / third-degree AV block, or right bundle-branch block with left hemiblock, unless a pacemaker can sustain rhythm; cardiogenic shock; and known hypersensitivity. Prior MI / significant structural disease AF restrictions and label recent-MI avoidance are essential additional eligibility limits, not inaccurately relabeled as every item in the formal contraindications section.

The ruled boxed text within WARNINGS describes excess death / nonfatal cardiac arrest in post-MI CAST patients treated for non-life-threatening ventricular ectopy, and ventricular proarrhythmia reported with AF / flutter, particularly chronic AF. CAST’s observed rate is not an individualized risk estimate for every indication. The warning argues against use for non-life-threatening ventricular arrhythmias and notes no demonstrated survival benefit.

Reported effects include dizziness, visual blurring / disturbance, headache, dyspnea, nausea, fatigue, palpitations and chest discomfort. Serious effects include conduction block, proarrhythmia, worsening CHF and rarely liver dysfunction or blood abnormalities. Investigate unexplained jaundice or cardiac symptoms; trial rates from different arrhythmia populations are not pooled into one universal risk.

Amiodarone can substantially increase exposure: reduce the usual flecainide dose 50% and monitor closely with levels strongly recommended. CYP2D6 inhibitors can increase concentrations; the label cites quinidine, and official AF slides also list duloxetine, fluoxetine and paroxetine. Cimetidine can increase exposure; phenytoin, phenobarbital and carbamazepine increase elimination. Do not invent a fixed adjustment for every inhibitor / inducer.

Propranolol / flecainide can increase each other’s concentrations and add negative inotropy; digoxin concentrations may rise. Verapamil or disopyramide co-use should occur only after clinician benefit / risk judgment; selected label experience with diltiazem / nifedipine is too limited to recommend the combination. Guideline AV nodal blockade for selected cardioversion patients is not proof that every rate-control combination is safe.

Milk inhibits absorption in infants; weaning or gastroenteritis-related intake reduction can increase exposure and may require dose reduction / level checks. Major dietary changes and all new medicines need review. Correct electrolyte disturbance; carefully plan switching from other antiarrhythmics rather than automatically applying a washout or overlap schedule.

The label has insufficient controlled human pregnancy data and adverse animal findings; use requires benefit / risk judgment. Official AF guidance considers flecainide reasonable for selected pregnant patients without structural heart disease based on history of use; this is not proof of zero fetal risk. Flecainide is present in human milk, sometimes above maternal plasma concentration; assess maternal need and infant risk rather than assert universal breastfeeding safety. Labor / delivery effects are unknown.

Pediatric use must be directly supervised by an experienced arrhythmia cardiologist, begun with hospital monitoring, and supported by ECG / trough checks after initiation or changes and at first-year follow-up. Structural heart disease increases pediatric cardiac-arrest risk. Older adults may eliminate the drug somewhat more slowly; assess renal function, conduction and medicines rather than invent an age-only cap.

Renal impairment prolongs exposure, though CrCl alone does not fully predict clearance. Follow the dose / level distinctions above. Significant hepatic disease can markedly slow elimination and requires exceptional benefit / risk justification plus frequent monitoring. Hemodialysis removes only a small fraction and is not an effective substitute for careful dosing.

Flecainide is a class Ic antiarrhythmic that slows intracardiac conduction, most prominently in the His–Purkinje system; negative inotropic effects can impair ventricular performance. Rhythm suppression does not establish survival benefit.

Oral absorption is nearly complete, with usual peaks around 3 hours (range 1–6) and little food / antacid effect. Typical patient half-life is 12–27 hours, averaging about 20. CYP2D6 contributes to metabolism and unchanged urinary elimination varies; renal / hepatic disease and interacting drugs can prolong exposure. Highly alkaline urine can slow elimination, but no home urine-manipulation regimen is recommended. Plasma concentration and clinical conduction response both matter.

Confirm indication, prior MI / structural disease and ventricular function before use. Check ECG / conduction, renal / hepatic function, electrolytes, interacting medicines and CHF symptoms; use appropriate rhythm monitoring at initiation. Obtain trough levels when indicated, especially severe renal / hepatic disease or amiodarone. Pediatric label checks use trough<1 hour pre-dose plus ECG after at least 5 doses following initiation / change, and at clinical follow-up in the first year. Pacemaker thresholds require their own checks; no universal ECG cutoff algorithm is invented.

Take only the prescribed tablet schedule and do not add a loading dose, double an uncertain dose or independently stop / switch rhythm medicines. Report syncope, rapid or slow heartbeat, worsening breathlessness / edema, chest pain or jaundice promptly. Dizziness or visual disturbance can impair driving. Caregivers must report infant milk-intake changes. A pill-in-the-pocket plan is a distinct monitored-tested specialist instruction.

Overdose can be fatal through conduction block, ventricular arrhythmias, hypotension or cardiac failure. Seek emergency medical / Poison Control help immediately; treatment may require prolonged monitoring, airway support, inotropes or pacing. Dialysis is ineffective for substantial removal and there is no home reversal strategy.

Product

Amneal flecainide acetate 50 mg tablet

Route

Oral; immediate-release prescription

Appearance

White round unscored; AN 641

Example package

Bottle 100 · NDC 53746-641-01

Selected tablets:50 mg (white round AN 641, unscored),100 mg (white round AN 642, bisected) and 150 mg (white oval AN 643, bisected). These are flecainide acetate strengths. Other manufacturers have different imprints; foreign IV / extended-release or compounded forms are outside this source scope.

Store selected tablets at 20–25°C in a tight, light-resistant container. Keep out of children’s reach and follow the actual dispensing label / expiry. No reviewed label supports a generic compounded-liquid stability or universal crushing / feeding-tube procedure.